As of 30 November 2025, the FOXO3-based age‑reversal work that Friedberg was referring to is still at the primate/preclinical stage. The key 2025 Cell paper by Lei et al. reports systemic age‑reversal effects in aged macaques using FOXO3‑enhanced, senescence‑resistant mesenchymal progenitor cells (SRCs) and attributes much of the effect to exosome‑mediated mechanisms, but it is entirely in non‑human primates and in vitro models, not humans. (sciencedirect.com) Follow‑on commentaries in Cell Regeneration and related outlets explicitly frame this work as a proof‑of‑concept that positions FOXO3‑enhanced MPCs/SRC‑exosomes as promising candidates for future clinical anti‑aging interventions, again without mentioning any ongoing human trials. (cellregeneration.springeropen.com) Popular and expert summaries likewise describe the therapy as early‑stage and “years away from real‑world use,” underscoring that translation to human trials has not yet happened. (biohackingnews.org) A targeted search of trial registries and the scientific literature through late 2025 finds FOXO3 in basic/translational contexts but no registered human clinical trials testing FOXO3‑engineered stem cells or their exosomes as systemic age‑reversal therapies analogous to the macaque study. Instead, all detailed reports match the same preclinical FOXO3‑SRC primate work. (pubmed.ncbi.nlm.nih.gov)

However, Friedberg’s prediction is about the situation “over the next couple of years”—i.e., roughly by 2027. Since 2027 has not yet arrived, we cannot know whether such human trials will in fact be underway by that time, even though they are not underway yet in 2025. Therefore the prediction cannot be definitively graded now and is best classified as inconclusive (too early) rather than right or wrong.